In vitro pharmacological inhibition of human vascular smooth muscle cell proliferation for the prevention of hemodialysis vascular access stenosis

Blood Purification

Volumn 22, Issue 3, 2004, Pages 307-312

  Masaki, Takahisa ^a,c   Kamerath, Craig D ^a   Kim, Seung Jung ^a   Leypoldt, John K ^a,b   Mohammad, Syed F ^a,b   Cheung, Alfred K ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b University of UT   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anti proliferative drugs; Dipyridamole; Hemodialysis; Paclitaxel; Stenosis; Vascular access; Vascular smooth muscle cells

Indexed keywords

ACETYLSALICYLIC ACID; BROMINE DERIVATIVE; DIPYRIDAMOLE; ENALAPRILAT; HEPARIN; HYDROXYUREA; INDOMETACIN; METHYLTHIAZOTETRAZOLIUM 3 (4,5 DIMETHYLTHIAZOL 2 YL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; PACLITAXEL; TIROFIBAN; TRANILAST; UNCLASSIFIED DRUG; VERAPAMIL;

AORTA MEDIA; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; HEMODIALYSIS VASCULAR ACCESS STENOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; STATISTICAL SIGNIFICANCE; STENOSIS; VASCULAR ACCESS; VASCULAR SMOOTH MUSCLE;

ANTINEOPLASTIC AGENTS; AORTA; CATHETERS, INDWELLING; CELL PROLIFERATION; CELLS, CULTURED; CONSTRICTION, PATHOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; HUMANS; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; PLATELET AGGREGATION INHIBITORS; RENAL DIALYSIS; VASODILATOR AGENTS;

EID: 4444372917     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078785     Document Type: Article

References (34)

1. Schwab SJ: Vascular access for hemodialysis. Kidney Int 1999; 55: 2078-2090.
2. Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC: Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 1989; 80: 1726-1736.
3. MacDonald JD, Gyorke A, Jacobs JM, Mohammad SF, Sunderland PM, Reichman MV: Acute phase vascular endothelial injury: A comparison of temporary arterial occlusion using an endovascular occlusive balloon catheter versus a temporary aneurysm clip in a pig model. Neurosurgery 1994; 34: 876-881.
4. Walker LN, Bowen-Pope DF, Ross R, Reidy MA: Production of platelet-derived growth factor-like molecules by cultured arterial smooth muscle cells accompanies proliferation after arterial injury. Proc Natl Acad Sci USA 1986; 83: 7311-7315.
5. 1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90: 456-461.
6. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM: Anti-platelet therapy in graft thrombosis: Results of a prospective, randomized, double-blind study. Kidney Int 1994; 45: 1477-1483.
7. Harvey R, Bredenberg CE, Couper L, Himmelfarb J: Aspirin enhances platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Vasc Surg 1997; 25: 689-695.
8. Gresele P, Arnout J, Deckmyn H, Vermylen J: Mechanism of the antiplatelet action of dipyridamole in whole blood: Modulation of adenosine concentration and activity. Thromb Haemost 1986; 55: 12-18.
9. Himmelfarb J, Couper L: Dipyridamole inhibits PDGF- and bFGF-induced vascular smooth muscle cell proliferation. Kidney Int 1997; 52: 1671-1677.
10. Proimos G: Platelet aggregation inhibition with glycoprotein IIb-IIIa inhibitors. J Thromb Thrombolysis 2001; 11: 99-110.
11. Clowes AW, Karnovsky MJ: Failure of certain antiplatelet drugs to affect myointimal thickening following arterial endothelial injury in the rat. Lab Invest 1977; 36: 452-464.
12. Kenagy RD, Clowes AW: Blockade of smooth muscle cell migration and proliferation in baboon aortic explants by interleukin-1b and tumor necrosis factor-α is nitric oxide-dependent and nitric oxide-independent. J Vasc Res 2000; 37: 381-389.
13. Block LH, Emmons LR, Vogt E, Sachinidid A, Vetter W, Hoppe J: Ca 2+ channel blockers inhibit the action of recombinant platelet-derived growth factor in vascular smooth muscle cells. Proc Natl Acad Sci USA 1989; 86: 2388-2392.
14. Munro E, Patel M, Chan P, Betteridge L, Gallagher K, Schachter M, Wolfe J, Sever P: Effect of calcium channel blockers on the growth of human vascular smooth muscle cells derived from saphenous vein and vascular graft stenoses. J Cardiovasc Pharmacol 1994; 23: 779-784.
15. Law M, Colburn M, Hajjar G, Gelabert H, Quinones-Baldrich W, Moore W: Suppression of intimal hyperplasia in a rabbit model of arterial balloon injury by enalaprilat but not dimethyl sulfoxide. Ann Vasc Surg 1994; 8: 158-165.
16. Albert D, Bluestein H: DNA synthesis inhibitors block protein synthesis in the human lymphocyte. Int J Immunopharmacol 1984; 6: 147-153.
17. Gelmon K: The taxoids: Paclitaxel and docetaxel. Lancet 1994; 344: 1267-1272.
18. Axel DI, Kunert W, Goeggelmann C, Overhoff M, Herdeg C, Kuettner A, Wild DH, Brehm BR, Riessen R, Koeveker G, Karsch KR: Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-645.
19. Grube E, Silber S, Hauptmann K, Mueller R, Buellesfeld L, Gerckens U, Russell M: TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107: 38-42.
20. Azuma H, Banno K, Yoshimura T: Pharmacological properties of N-(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′), a new antiatopic agents. British Journal of Pharmacology 1976; 58: 483-488.
21. Kusama H, Kikuchi S, Tazawa S, Katsuno K, Baba Y, Zhai YL, Nikaido T, Fujii S: Tranilast inhibits the proliferation of human coronary smooth muscle cell through the activation of p21 waf1 . Atherosclerosis 1999; 143: 307-313.
22. Tamai H, Katoh O, Suzuki S, Fujii K, Aizawa T, Takase S, Kurogane H, Nishikawa H, Sone T, Sakai K, Suzuki T, for the TREAT Study Group: Impact of tranilast on restenosis after coronary angioplasty: Tranilast Restenosis Following Angioplasty Trial (TREAT). Am Heart J 1999; 138: 968-975.
23. Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986; 89: 271-277.
24. Hardman J, Limbird L, Gilman A: Goodman and Gilman's The Pharmacological Basis of Therapeutics, ed 9. New York, McGraw-Hill, 1996.
25. Chan P, Patel M, Betteridge L, Munro E, Schachter M, Wolfe J, Sever P: Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosis. Lancet 1993; 341: 341-342.
26. Brody WR, Brown JW, Reitz BA, Fry DL, Michaelis LL: Effects of dipyridamole and methylprednisolone on intimal thickening in vein grafts. J Thorac Cardiovasc Surg 1977; 73: 602-604.
27. Clowes AW, Clowes MM, Vergel SC, Muller RK, Powell JS, Hefti F, Baumgartner HR: Heparin and cilazapril together inhibit injuryinduced intimal hyperplasia. Hypertension 1991; 18(suppl 4):1165-1169.
28. Churchill D, Siegel C, Minor S, West M, Raizner A: Enalapril in the prevention of restenosis following intracoronary intervention. Coron Artery Dis 1993; 4: 461-467.
29. Gradzki R, Dhingra RK, Port FK, Roys E, Weitzel WF, Messana JM: Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts. Am J Kidney Dis 2001; 38: 1240-1244.
30. McEvoy GK: American Hospital Formulary Service Drug Information. Bethesda, American Society of Health-System Pharmacists, 2000.
31. Fukuyama J, Miyazawa K, Hamano S, Ujiie A: Inhibitory effects of tranilast on proliferation, migration, and collagen, synthesis of human vascular smooth muscle cells. Can J Physiol Pharmacol 1996; 74: 80-84.
32. 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 1995; 118: 213-221.
33. Holmes DJ, Savage M, LaBlanche J, Grip L, Serruys P, Fitzgerald P, Fischman D, Goldberg S, Brinker J, Zeiher A, Shapiro L, Willerson J, Davis B, Ferguson J, Popma J, King Sr, Lincoff A, Tcheng J, Chan R, Granett J, Poland M: Results of prevention of restenosis with tranilast and its outcomes (PRESTO) trial. Circulation 2002; 106: 1243-1250.
34. Zentner GM, Rathi R, Shih C, McRea JC, Seo MH, Oh H, Rhee BG, Mestecky J, Moldoveanu Z, Morgan M, Weitman S: Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 2001; 72: 203-215.